Journals / Erciyes Medical Journal / 2021 / Cilt: 43 - Sayı: 1

Clinical and Molecular Spectrum of TuberousSclerosis Complex Patients: Identification of ThreeNovel Mutations

Pages
54–60
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In this study, in addition to the three novel mutations reported herein, the spectrum of TSC1 and TSC2 genemutations and their phenotypes were reported.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous syndrome.
📊
Key Findings & Data:TSC arises from mu tations in either TSC1, at 9q34, or TSC2, at 16p13.3.
💡
Conclusion & Impact:Conclusion: In this study, in addition to the three novel mutations reported herein, the spectrum of TSC1 and TSC2 genemutations and their phenotypes were reported.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous syndrome. TSC arises from mu tations in either TSC1, at 9q34, or TSC2, at 16p13.3. Skin lesions, such as hypomelanotic macules, facial angiofibromas,shagreen patches, and ungual fibromas, are frequently seen in these patients. The present study aims to investigate clinicalmanifestations, molecular findings and phenotype-genotype correlations in 17 patients with TSC. Materials and Methods: TSC1 and TSC2 molecular analyses were performed on a next-generation sequencing platform(Illumina MiSeq). Variant interpretation was made in accordance with the American College of Medical Genetics 2015 rec ommendations. Results: Four patients carried a heterozygous mutation in TSC1, while the remaining seven carried mutations in TSC2.Three novel variants in TSC2 were defined. Sequencing failed to detect a mutation in six patients. In only one of these pa tients, multiplex ligation-dependent probe amplification (MLPA®) could be performed, and a large deletion in the TSC1 genewas detected. A wide spectrum of phenotypic features was noted throughout the study group. Dermatological findings wereobserved in almost all patients. Conclusion: In this study, in addition to the three novel mutations reported herein, the spectrum of TSC1 and TSC2 genemutations and their phenotypes were reported.

🔖

Cite This Article

IŞIK, E., TEKGÜL, H., KANTAR, M., ÇOĞULLU, Ö., ATİK, T., SOLMAZ, A. E., TEREK, D., GÖKBEN, S., KÜLTÜRSAY, N., ÖZKINAY, F., LEVENT, E., ONAY, H. (2022). Clinical and Molecular Spectrum of TuberousSclerosis Complex Patients: Identification of ThreeNovel Mutations. Erciyes Medical Journal, Cilt: 43 - Sayı: 1, 54–60. https://ajindex.com/articles/502211

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49(4): 243– 54
  2. Martin KR, Zhou W, Bowman MJ, Shih J, Au KS, Dittenhafer-Reed KE, et al. The genomic landscape of tuberous sclerosis complex. Nat Commun 2017; 8: 15816
  3. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, et al. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003; 21(6): 577–81
  4. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4(7): 1073–81
  5. Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010; 7(8): 575–6
  6. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am J Hum Genet 2016; 99(4): 877–85
  7. Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A, Batzoglou S. Identifying a high fraction of the human genome to be under selective constraint using GERP++. PLoS Comput Biol 2010; 6(12): e1001025
  8. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17(5): 405–24
  9. Jacks SK, Witman PM. Tuberous Sclerosis Complex: An Update for Dermatologists. Pediatr Dermatol 2015; 32(5): 563–70
  10. Ding Y, Wang J, Zhou S, Zhou Y, Zhang L, Yu L, et al. Genotype and Phenotype Analysis of Chinese Children with Tuberous Sclerosis Complex: A Pediatric Cohort Study. Frontiers in Genetics 2020; 11: 204
  11. Curatolo P, Moavero R, Roberto D, Graziola F. Genotype/Phenotype Correlations in Tuberous Sclerosis Complex. Semin Pediatr Neurol 2015; 22(4): 259–73
  12. Almobarak S, Almuhaizea M, Abukhaled M, Alyamani S, Dabbagh O, Chedrawi A, et al. Tuberous Sclerosis Complex: Clinical Spectrum and Epilepsy: A Retrospective Chart Review Study. Transl Neurosci 2018; 9: 154–60
  13. Ismail NF, Rani AQ, Nik Abdul Malik NM, Boon Hock C, Mohd Azlan SN, Abdul Razak S, et al. Combination of Multiple Ligation-Depen